NewAmsterdam Pharma (NAMS) started a $300 million underwritten public offering of ordinary shares and prefunded warrants to certain investors.
Underwriters in the offering will have a 30-day option to purchase up to an additional $45 million of ordinary shares, the company said Tuesday in a statement.
"The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when" the offering may be completed or the actual size or terms, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.